Testosterone laboratory testing and measurement (coverage criteria)
Customize your policy alerts
Sign up for all Premera Bluecross policy alerts
Know when Premera Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Defines when serum total, free, bioavailable testosterone and related hormone tests (e.g., SHBG, albumin, estradiol, DHT) are reimbursable, not reimbursable, and provides analytical/testing guidance; applies to Premera Bluecross coverage determinations.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Policy Summary
PayerPremera Bluecross
PolicyTestosterone laboratory testing and measurement (coverage criteria)
Key ActionDo not use free or bioavailable testosterone as the primary test — measure total testosterone first and document two separate morning totals when diagnosing hypogonadism.
Corrected policy statements to indicate measurement of serum free testosterone and/or bioavailable testosterone as a primary test and for asymptomatic individuals or those with non-specific symptoms is not reimbursable.
2Initial total testosterone screening recommendation
±6.4%CDC HoSt acceptance limit
2–3 moMonitoring frequency (first year)
<50 ng/dLNCCN castrate threshold
90-dayProvider notification period
Coverage Criteria for Testosterone and Related Tests
inv-01: Covered: Total testosterone and related tests
Measurement of serum total testosterone is reimbursable when any one of the following applies:
Symptoms of androgen deficiency or excess (individuals assigned male at birth): For individuals assigned male at birth with symptoms of androgen deficiency or androgen excess: initial screening requires two total testosterone measurements at least 24 hours apart; if initial screening is normal but symptoms persist, repeat testing is allowed no sooner than 60 days after the initial screening; monitoring of treatment response is reimbursable for individuals taking enzyme inhibitors for prostate cancer; monitoring for individuals receiving testosterone replacement therapy (every 2–3 months for the first year after initiation or after a dosage change; annually thereafter); baseline, during treatment, and monitoring for gender-dysphoric/gender-incongruent individuals; and for symptomatic individuals assigned female at birth being evaluated for androgen excess (e.g., PCOS, functional hypothalamic amenorrhea).
Direct from Indications 1.a; includes monitoring intervals and repeat-testing guidance
Disorders of genital development and related diagnostics: For individuals with ambiguous genitalia, hypospadias, or microphallus, measurement of serum dihydrotestosterone (DHT) for diagnosis of 5-alpha reductase deficiency is reimbursable.
Direct from Indications 5
Pre-therapy estradiol for gynecomastia: Prior to initiating testosterone therapy for individuals assigned male at birth with gynecomastia, a once-per-lifetime serum estradiol measurement is reimbursable.
Direct from Indications 4
inv-02: Covered: Supplemental testing
Additional reimbursable testing when specified conditions exist:
Annual supplemental testing for confirmed low/borderline TT: For individuals assigned male at birth with total testosterone confirmed as low or borderline who have hypogonadism, gynecomastia, or other testicular hypofunction, annual measurement of serum free testosterone, sex hormone–binding globulin (SHBG), and/or albumin is considered reimbursable.annual
Direct from Indications 2
Free/bioavailable testosterone when SHBG disorder suspected: When a disorder that alters SHBG is suspected, measurement of serum free testosterone using a medically accepted algorithm based on total testosterone, SHBG, and/or albumin or measurement of bioavailable testosterone is considered reimbursable.
Direct from Indications 3; calculated fT or bioavailable assays preferred over direct immunoassays
inv-03: Not medically necessary / Not reimbursable
Tests or situations considered not reimbursable:
Primary free or bioavailable testosterone testing not covered: Measurement of serum free testosterone and/or bioavailable testosterone as a primary test (i.e., in the absence of a prior serum total testosterone measurement) is not reimbursable.
Direct from Indications 6
Asymptomatic or non-specific symptoms not covered: For asymptomatic individuals or for individuals with non-specific symptoms, measurement of serum total testosterone, free testosterone, and/or bioavailable testosterone is not reimbursable.
Direct from Indications 7
Salivary testosterone testing not covered: The use of saliva for the measurement of testosterone is not reimbursable.
Direct from Indications 8
Other DHT uses not covered:
inv-04: Guideline-based coverage criteria
Covered when recommendations from specialty societies are followed (examples below):
Diagnosis of male hypogonadism per society guidance: Patient has signs/symptoms of testosterone deficiency AND unequivocally low serum total testosterone on two separate early-morning samples (or low free testosterone by validated calculation or equilibrium dialysis when indicated).AUA: total testosterone < 300 ng/dL supports diagnosis
Includes recommendation to measure LH/FSH to distinguish primary vs secondary hypogonadism and evaluate for reversible causes; based on ES, AUA, CUA/CSAM, EAA guidance
Pre-therapy baseline testing for men: Before initiating testosterone therapy obtain baseline serum total testosterone and hematocrit (and PSA in men >40 years per AUA/other guidance).PSA and hematocrit as clinically indicated
Society recommendations call for documenting baseline values for monitoring
Monitoring during testosterone therapy and transgender care:
inv-05: Diagnostic testing criteria
Testing and confirmation of hypogonadism is supported when following these diagnostic steps:
Confirmatory testing for suspected hypogonadism
Timing: Collect samples between 7 AM and 11 AM or within 3 hours after waking for shift workers.7–11 AM (or within 3 hours of waking)
CUA/CSAM and other societies specify sampling window
Supplemental hormone measurements: Measure LH and prolactin to characterize gonadal status; consider measuring SHBG and calculating free or bioavailable testosterone when SHBG-altering conditions exist or total T is borderline (~8–12 nmol/L); measure FSH when assessing spermatogenesis or infertility; measure estradiol only in specific scenarios when validated mass spectrometry is available.clinical indication-dependent
EAA, EAU, CUA/CSAM guidance
inv-06: ADT monitoring
Monitoring for patients on androgen deprivation therapy (ADT):
ADT monitoring: Document castrate serum testosterone (<50 ng/dL) when clinically indicated and monitor PSA and testosterone every 3–6 months; with intermittent ADT, monitor closely off-treatment and consider switching to continuous ADT on progression.<50 ng/dL
NCCN guidance for castrate-level documentation and monitoring intervals
inv-07: Coverage summary
Covered when ALL of the following are met (policy-level summary):
Primary covered condition: Measurement of serum total testosterone may be considered reimbursable when performed for indications explicitly outlined in this policy and when documentation requirements (e.g., morning sample timing, assay certification, and indication-specific notes) are met.
Policy-level summary referencing coverage statements and documentation expectations
Explicitly not covered primary uses: Measurement of serum free testosterone and/or bioavailable testosterone as a primary test and testing in asymptomatic individuals or for non-specific symptoms is not reimbursable (corrected effective statement).
Corrected policy statement effective for dates of service on or after September 4, 2026
The policy excludes use of saliva specimens for testosterone measurement from reimbursement. Additionally, measurement of serum dihydrotestosterone (DHT) is not reimbursable except when ordered for the specific, listed indications in this policy. Claims for salivary testosterone testing or for serum DHT outside the specified diagnostic uses may be denied.
Direct analog-based immunoassays and commercially available kits that report direct free testosterone (fT) are specifically discouraged due to poor accuracy and reliability. When free testosterone assessment is required, clinicians should prefer calculated fT based on total testosterone, SHBG, and albumin or measure fT by equilibrium dialysis rather than using direct immunoassays.
For children with only pubic hair or body odor and no other signs of puberty, routine ordering of LH/FSH together with estradiol or testosterone is discouraged. Premature adrenarche is usually benign and does not require activation of the hypothalamic–pituitary–gonadal axis evaluation; such hormone panels in isolated adrenarche may be inappropriate and are not recommended.
Measurement of serum free testosterone and/or bioavailable testosterone as a primary test (i.e., without a prior serum total testosterone) is not reimbursable. The corrected policy statement clarifies that claims for primary use of free or bioavailable testosterone testing, or testing for asymptomatic individuals or those with non-specific symptoms, are not covered effective for dates of service on or after September 4, 2026.
The policy excludes primary testing with free or bioavailable testosterone, testing performed in asymptomatic individuals or for non-specific symptoms, and salivary testosterone testing from reimbursement. These uses are considered not medically necessary due to insufficient evidence of clinical benefit.
Major specialty guidance advises against routine population screening for hypogonadism. The European Society (ES) recommends diagnosing hypogonadism only in symptomatic men with consistently low total (and when indicated, free) testosterone and advises against routine screening of the general male population. ACOG likewise recommends against routine monitoring of serum androgens in adolescents with hyperandrogenism and does not support routine population screening.
The European Academy of Andrology (EAA) does not recommend routine measurement of serum estradiol. Estradiol testing is suggested only when a validated mass spectrometry–based method is available or in rare cases of suspected severe estrogen deficiency.
Use of free and/or bioavailable testosterone assays as the primary diagnostic test in lieu of total testosterone, and testing in asymptomatic individuals or those with non-specific symptoms, are not reimbursable. Total testosterone measured on appropriately timed morning samples remains the preferred initial test; supplemental free/bioavailable testing is covered only when criteria in this policy are met.
Provider Responsibilities, Documentation, and Billing Guidance
Billing Rule
Coverage tied to indicated CPT codes
Reimbursement is allowed for the listed testosterone and related hormone CPT codes when performed for the policy’s specified indications (see Indications).
Obtain baseline PSA in men over age 40 and measure hemoglobin/hematocrit prior to initiating testosterone therapy; these baseline labs support safe initiation and monitoring of therapy.
PSA: measure prior to therapy in men >40 (AUA/Endocrine Society guidance referenced).
Background and Clinical Context
Testosterone is produced by Leydig cells in the testes in males and by the ovaries and adrenal glands in females and is central to sexual development, maintenance of secondary sexual characteristics, spermatogenesis, and conversion to dihydrotestosterone and estradiol. Disorders of testosterone production or action underlie conditions such as hypogonadism and polycystic ovary syndrome; measurement and interpretation of testosterone require attention to specimen timing, assay method, and clinical context.
Key Definitions and Laboratory Methods
Total testosterone (TT)
DefinitionTotal testosterone (TT) = sum of free and protein-bound testosterone in serum
Role in evaluationPrimary initial laboratory measurement for evaluation of androgen status
Sampling guidanceCollect early-morning fasting samples and, if low, confirm on two separate mornings
Free and bioavailable testosterone
Free testosterone (fT)The unbound fraction of circulating testosterone; represents ~1–4% of total testosterone
Bioavailable testosteroneSum of free testosterone plus albumin-bound testosterone (loosely bound fraction)
Policy Revision History
2026-09-04correctionLatest
Corrected policy statements to specify that measurement of serum free testosterone and/or bioavailable testosterone as a primary test and for asymptomatic individuals or those with non-specific symptoms is not reimbursable; effective for dates of service on or after September 4, 2026 following 90-day provider notification.
2026-02-06new_policy_effective
New policy on routine testosterone testing became effective for dates of service on or after February 6, 2026 after 90-day provider notification; measurement of serum total testosterone may be considered reimbursable for indications outlined in the policy when criteria are met.
Policy Summary
PayerPremera Bluecross
PolicyTestosterone laboratory testing and measurement (coverage criteria)
Key ActionDo not use free or bioavailable testosterone as the primary test — measure total testosterone first and document two separate morning totals when diagnosing hypogonadism.
For all other situations not mentioned as reimbursable above, measurement of serum dihydrotestosterone is not reimbursable.
Direct from Indications 9
Monitor serum testosterone and hematocrit after initiation (e.g., 3–6 months) and at least annually thereafter; for transgender males, measure every three months until physiologic male range achieved, then every 6–12 months; for injections, time sampling appropriately (midway between injections or peak/trough per regimen).
3–6 months initially, then annually; transgender: q3 months until target, then q6–12 months
Based on ES, CUA/CSAM, and transgender care guidance (Hembree et al.)
Free testosterone assessment methodology: When free testosterone assessment is needed, use calculated free testosterone based on TT, SHBG, and albumin or equilibrium dialysis; do not use direct analog-based free testosterone immunoassays because they are inaccurate.Equilibrium dialysis = gold standard
Explicit technical comment from ES and reiterated by EAA and others
Avoid unnecessary pediatric testing:
Do not routinely order LH/FSH with estradiol or testosterone for children with isolated pubic hair/body odor without other signs of puberty (premature adrenarche typically benign).
clinical presentation
AAP Choosing Wisely guidance
Free testosterone associationSome data indicate fT <225 pmol/L is associated with hypogonadism, though exact fT cut-off remains uncertain
Hematocrit/hemoglobin: obtain baseline prior to initiating testosterone replacement.
Documentation Required
ADT monitoring documentation
For patients on androgen deprivation therapy, document castrate serum testosterone (<50 ng/dL) when clinically indicated and monitor PSA and testosterone at the recommended intervals.
Maintain documentation of castrate level (<50 ng/dL).
Monitor PSA and testosterone every 3–6 months per NCCN guidance.
Prior Authorization
Prior authorization
The policy text does not specify any formal payer prior authorization requirements or prior authorization codes for testosterone or related hormone testing.
No explicit prior authorization rules are provided in the policy excerpt.
Step Therapy
Testing sequence preference
Use serum total testosterone as the initial laboratory evaluation; free or bioavailable testosterone testing is reimbursable only when indicated (e.g., low/borderline total T or suspected SHBG perturbation).
Initial evaluation: total testosterone first (morning, fasting samples).
Free/bioavailable tests reimbursable as supplemental testing when clinical criteria met.
Step Therapy
Sequential testing preference
If total testosterone is near the lower limit or conditions affecting SHBG are present, proceed to calculated free testosterone using total T, SHBG, and albumin or use equilibrium dialysis rather than direct immunoassays.
Calculated free T based on TT, SHBG, and albumin or equilibrium dialysis is preferred.
Avoid direct analog-based free testosterone immunoassays for this purpose.
Note
Follow guideline-based testing algorithms
Providers should follow documented clinical indications and specimen/assay guidance when ordering tests to support coverage decisions.
Ensure orders align with guideline-based indications and testing algorithms.
Step Therapy
Step therapy
No step therapy requirements are specified by the policy for testosterone or related hormone testing.
Policy explicitly states no step therapy requirements in this section.
Documentation Required
Specimen timing and assay certification
Document symptom-based indications and, when applicable, prior total testosterone results; use CDC HoSt–certified or validated assays for total testosterone measurement.
Record the clinical signs/symptoms prompting testing.
When available, use assays certified by the CDC HoSt/Testosterone program (±6.4% standardization).
Documentation Required
Required baseline and follow-up documentation
When diagnosing hypogonadism, document two separate early-morning total testosterone measurements and baseline hematocrit/hemoglobin prior to initiating therapy.
Two morning TT measurements at least 24 hours apart (repeat testing no sooner than 60 days if initial normal but symptoms persist).
Record baseline testosterone and hematocrit/hemoglobin before starting treatment.
Documentation Required
Record sample timing
Record the time of morning serum collection (samples should be collected between 7 AM and 11 AM or within 3 hours after waking for shift workers) to support interpretation.
Document exact collection time to verify it falls within the recommended window.
Documentation Required
Documentation of indication
Document the specific clinical indication or criteria that justify ordering testosterone or related hormone testing to support reimbursement in accordance with policy coverage statements.
Include symptom/sign details or guideline-based indication on the order or in the chart.
Denial Risk
Denial triggers for unsupported indications
Ordering free or bioavailable testosterone as the primary test without a prior total testosterone measurement is not reimbursable, and testing in asymptomatic individuals or for non-specific symptoms is deniable.
Claims for primary free/bioavailable testing without prior total T risk denial.
Testing for asymptomatic individuals or nonspecific symptoms is not reimbursable.
Documentation Required
Accurate assay and measurement practice
Do not use direct analog-based free testosterone immunoassays due to inaccuracy; prefer serum total testosterone measured on two separate mornings and calculate free testosterone using validated algorithms or use equilibrium dialysis when indicated.
Direct free-T immunoassays are discouraged; use calculated free T (TT, SHBG, albumin) or equilibrium dialysis.
Total T should be measured twice on morning samples using validated/standardized assays.
Denial Risk
Avoid unnecessary hormone panels in isolated adrenarche
Avoid ordering LH/FSH with estradiol or testosterone for children who present only with pubic hair or body odor and no other signs of puberty, as premature adrenarche is usually benign.
Such hormone panels in isolated adrenarche are discouraged and may be considered inappropriate.
Denial Risk
Non-reimbursable primary/broad testing
Measurement of serum free testosterone and/or bioavailable testosterone as a primary test and testing in asymptomatic individuals or those with non-specific symptoms is not reimbursable and claims for these uses may be denied.
Free/bioavailable tests as primary diagnostics are non-reimbursable.
Testing in asymptomatic or nonspecific-symptom individuals is non-reimbursable.
Measurement methods
Preferred assessment via calculated algorithms using TT, SHBG, and albumin or by equilibrium dialysis when indicated; direct immunoassays discouraged
CDC HoSt/Testosterone certification
CDC Hormone Standardization (HoSt) programAssay certification ensures calibration to CDC reference with predefined acceptance limits (±6.4%)
Recommended useStrong recommendation to use CDC HoSt-certified assays for total testosterone measurement
Certification monitoringCDC verifies calibration by analyzing serum material with assigned reference values every 6 months
Equilibrium dialysis
Gold standard for fTEquilibrium dialysis is the laboratory gold standard for determining free serum testosterone
Technical considerationsTechnically demanding, sensitive to pH, ionic strength, and temperature; limited availability and higher cost
DependencyRelies on accuracy of total testosterone measurement to ensure valid results
LC-MS/MS / ID-UPLC-MS/MS
Mass spectrometry methodsLC-MS/MS and ID-UPLC-MS/MS provide higher accuracy and lower variability than traditional immunoassays for testosterone
Sensitivity and suitabilityValidated MS methods demonstrate adequate sensitivity for low concentrations and improved inter-lab consistency
RecommendationEAU recommends LC-MS/MS as the most accurate standard for serum testosterone testing
Total testosterone (TT) — sampling & confirmation
Sampling timingCollect serum total testosterone in the early morning after fasting (commonly 7–11 AM)
ConfirmationWhen initial total testosterone is low, repeat measurement on at least two separate mornings to confirm low values
Clinical variability noteDue to considerable intra-individual variability, timing and fasting improve reproducibility
Free testosterone (fT) — method preference
Preferred approachCalculated free testosterone using TT, SHBG, and albumin is preferred over direct assays
Direct assays discouragedDirect commercial free-T immunoassays are inaccurate and should not be used
When to use equilibrium dialysisReserve equilibrium dialysis when calculated results are unreliable or for definitive assessment
Total, free, and bioavailable testosterone — summary
Total testosterone (TT)Circulating testosterone measured in serum; represents free plus protein-bound fractions
Free testosterone (fT)Unbound fraction; clinically relevant when SHBG altered or TT borderline and best estimated by calculation or equilibrium dialysis
Bioavailable testosteroneFree plus albumin-bound testosterone — the loosely bound fraction contributing to biologic activity
2025-11-01approval
Policy created and approved October 14, 2025 (recorded 11/01/25) as a new policy and added to Routine Test Management section.